Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-02
2007-10-02
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100, C424S141100, C424S145100
Reexamination Certificate
active
10724274
ABSTRACT:
The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
REFERENCES:
patent: 4704366 (1987-11-01), Juarez-Salinas et al.
patent: 4935496 (1990-06-01), Kudo
patent: 4946778 (1990-08-01), Ladner
patent: 5502167 (1996-03-01), Waldmann
patent: 5536814 (1996-07-01), Ruoslathi
patent: 5558864 (1996-09-01), Bendig
patent: 5639641 (1997-06-01), Pedersen
patent: 5677181 (1997-10-01), Parish
patent: 5693493 (1997-12-01), Robinson
patent: 5698417 (1997-12-01), Robinson
patent: 5705154 (1998-01-01), Dalie
patent: 5750078 (1998-05-01), Shitara
patent: 5770403 (1998-06-01), Dalie et al.
patent: 5874081 (1999-02-01), Parish
patent: 5922676 (1999-07-01), Pasqualini
patent: 6123941 (2000-09-01), Bissell et al.
patent: 6852318 (2005-02-01), Varner
patent: 2002/0172675 (2002-11-01), Varner
patent: 0 896 002 (1999-02-01), None
patent: WO95/14714 (1995-06-01), None
patent: WO95/14772 (1995-06-01), None
patent: WO95/22618 (1995-08-01), None
patent: WO97 33887 (1997-09-01), None
patent: WO99/55913 (1999-11-01), None
patent: WO99/58139 (1999-11-01), None
patent: WO 01/11086 (2001-02-01), None
patent: WO 01/53262 (2001-07-01), None
patent: WO 01/53297 (2001-07-01), None
patent: WO 02/79492 (2002-10-01), None
Rudikoff et al. Proceedings of the National Academy of Sciences, USA 79:1979-1983, 1982.
International Search Report dated Jul. 8, 2005.
Edelman and Castro, “Quantitative Image Analysis of Laser-Induced Choroidal Neovascularization in Rat,”Exp. Eye Res, 71:523-533 (2000).
PCT/US2004/010422 International search report, Feb. 8, 2005.
Wu, H., et. al., “The Expression Of Integrin Alph5beta1 And Transforming Growth Factor-Beta In Pulmonary Fibrosis Of Rat”Chinese Journal of Pathology, 28(6): abstract (1999).
Zhao, Ming Wei et. al., A Distinct Integrin-Mediated Phagocytic Pathway For Extracellular Matrix Remodeling By RPE Cells:Invest. Ophthalmol. Vis. Sci., 40(11):2713-2723 (1999).
Wilson, Sylvia et. al.,. “Fibronectin Fragments Promote Human Retinal Endothelial Cell Adhesion and Proliferation and ERK Activation Through Alph5beta1 Integrin and PI 3-Kinase”Invest. Ophthalmol. Vis. Sci., 44(4):1704-1715 (2003).
Loike, J.D. et. al., “Blockade Of Alpa 5 Beta 1 Integrins Reverses The Inhibitory Effect Of Tenacin On Chemotaxis Of Human Monocytes And Polymorphonuclear Leukocytes Through Three-Dimensional Gels Of Extracellular Matrix Proteins”Journal of Immunology166(12):7534-7542 2001.
Kim, Semi et.al., “Regulation Of Integrin Alpha5beta3-Mediated Endothelial Cell Migration And Angiogenesis By Integrin Alpha5beta1 And Protein Kinase A”Journal of Biological Chemistry, 275(43):33920-33928 (2000).
Grossniklaus, Hans et. al., “Immunohistochemical And Histochemcial Properties Of Surgically Excised Subretinal Neovascular Membranes In Age-Related Macular Degeneration”American Journal of Ophthalmology1 14(4):464-472 (1992).
Storgard, Chris M. et al., “Decreased Angiogenesis and Arthritic Disease in rabbits Treated with an ανβ3 Antagonist”,The Journal of clinical Investigation, vol. 103 (1999), pp. 47-54.
Argraves et al., J. Biol. Chem. 261(28):12922-12924 (1986).
Hackett, R., et al., 1996, Dermatotoxicology. 5thEdition. Ed. By F.B. Marzulli and H.I. Maibach. Hemisphere Publishing Corp., Washington, D.C.
Prouix et al., “Effect of quienscence on integrin α5β1 expression in human retinal pigment epithelium”Molecular Vision 9:473-481 (2003).
Pytela et al., Cell 40: 191-198 (1985).
Ryan, S.J.,The Development of an Experimantal Model of Subretinal Neovascularization in Disciform Macular Degeneration, Transactions of the American Ophthalmological Society 77: 707-745 (1979).
Ryan, S.J., “Subretinal Neovascularization: Natural History of an Experimental Model,” Archives of Ophthalmology 100: 1804-1809 (1982).
Thorpe et al., “Monoclonal Antibodies in Biological Clinical Applications,” 475-506 (1985).
Tolentino, M.J., et al., “Angiography of Fluoresceinated Anti-Vascular Endothelial Growth Factor Antibody and Dextrans in Experimental Choroidal Neovascularization,” Archives of Ophthalmology 118: 78-84 (2000).
Varner et al., “Antagonists of vascular cell integrin alpha 5 beta 1 inhibit angiogenesis,” Circulation 98(17) Supp. 'S!, 4166-4166 (Oct. 1998).
Varner et al., “Integrins and cancer,” Current Opinion in Cell Biology, 8(5): 724-30 (1996).
Varner et al., “Tumor angiogenesis and the role of vascular cell integrin alphavbeta3,” Important Advances in Oncology, (1996), 69-87.
Conforti, et al., “Human endothelial cells express integrin receptors on the luminal aspect of their membrane,”Blood, 80(2):437-446 (1992).
Bhaskar Vinay
Jeffry Ursula
Johnson Dale E.
Powers David
Ramakrishnan Vanitha
Biro Michael
Bristol Lynn
Helms Larry R.
Howrey LLP
PDL Biopharma, Inc.
LandOfFree
Chimeric and humanized antibodies to α5β1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric and humanized antibodies to α5β1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric and humanized antibodies to α5β1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3838208